FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bolzon Bradley J PhD			2. Issuer Name <b>and</b> Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner     Officer (give title Other (specify)								
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET				3. Date of Earliest Transaction (Month/Day/Year) 08/10/2020										below			belo			
(Street) CAMBRIDGE MA 02142				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									G. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
(City)	(St	ate) (2	(ip)												. 5.55					
		Table	I - Non-Deriva	tive	Secu	ırities	Acqı	uired,	Dis	posed	of, o	or B	Benefic	iall	y Own	ed				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			(A) or 3, 4 and 5)	d 5) 5. Amo Securit Benefic Owned Followi		es ally	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	e V	Am	ount	(A) o	r P	rice	Reported Transaction(s) (Instr. 3 and 4)		d tion(s)				
Common	Stock		08/10/2020				S <sup>(1)</sup>			725	D	\$	33.0382	2(2)	1,120	6,661		I	See Footnote <sup>(3)</sup>	
Common	Stock		08/10/2020				S <sup>(1)</sup>		5	,492	D	\$	33.0382	<u>2</u> (2)	6,80	3,922		I	See Footnote <sup>(4)</sup>	
Common	Stock		08/11/2020				S <sup>(1)</sup>			883	D	\$	33.0813	<b>3</b> (5)	1,12	5,778		I	See Footnote <sup>(3)</sup>	
Common	Stock		08/11/2020				S <sup>(1)</sup>		6	,692	D	\$	33.0813	<b>3</b> (5)	6,79	7,230		I	See Footnote <sup>(4)</sup>	
Common	Stock														2,01	7,016		I	See Footnote <sup>(6)</sup>	
Common	Stock														601,445			I	See Footnote <sup>(7)</sup>	
Common	Stock														1,4	491		D		
		Tal	ole II - Derivati (e.g., pu												Owned	d				
Derivative Conversion Date			3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)			ative ities red sed 3, 4	ed Expiration (Month/I		xercisable and on Date Day/Year)		mou Secur Inder Deriva	e and int of rities rlying ative rity (Instr. 4)	De Se	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
	of Respon			Code V (A) (D) Date Expiration Date Tit			itle	Amount or Number of Shares												

- 1. The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI").
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 to \$33.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- 3. Shares held by Versant Vantage I, Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 4. Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP-GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 to \$33.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- 6. Shares held by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 7. Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP is the general partner of Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

/s/ Robin L. Praeger, Attorney
- in - fact for Bradley J. 08/12/2020
Bolzon, PhD.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.